SCHEMBL1745291

SCHEMBL1745291

CC(C)(Oc1ccc(OC2CCc3ccccc32)cc1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.63
MAPK14 Q16539 1/20 0.63
FFAR1 O14842 4/20 0.55
PPARA Q07869 7/20 0.47
LMNA P02545 2/20 0.47
CYP2C9 P11712 2/20 0.47
TSHR P16473 2/20 0.47
BLM P54132 1/20 0.47
CYP2C19 P33261 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
PPARG P37231 7/20 0.43
IDO1 P14902 2/20 0.43
PPARD Q03181 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747245 0.84 FFAR1 (0.55) MAPK1MAPK14FFAR1PPARATSHR
SCHEMBL12017975 0.79 IDO1 (0.61) FFAR1IDO1
Nafenopin SCHEMBL184232 0.78 MAPK1 (1.00) MAPK1MAPK14PPARALMNACYP2C9
SCHEMBL1745136 0.77 FFAR1 (0.57) FFAR1PPARACYP2C9CYP2C19CYP1A2
SCHEMBL1746407 0.76 FFAR1 (0.60) FFAR1TSHRMEN1KMT2AMAPT
SCHEMBL1746615 0.76 FFAR1 (0.60) FFAR1LMNATSHRIDO1KDM4E
SCHEMBL8529487 0.76 IDO1 (0.54) FFAR1IDO1
SCHEMBL21142124 0.76 IDO1 (0.54) FFAR1CYP2D6IDO1
SCHEMBL1633343 0.74 FFAR1 (0.57) FFAR1
SCHEMBL1745432 0.74 FFAR1 (0.57) FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR MAPK1 1667/4885MAPK14 1874/4885FFAR1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.